A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma - Trial NCT06381141
Access comprehensive clinical trial information for NCT06381141 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cullinan Therapeutics Inc. and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cullinan Therapeutics Inc.
Timeline & Enrollment
Phase 1
Sep 01, 2024
Mar 01, 2027
Primary Outcome
Proportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs),Changes in Eastern Cooperative Oncology Group (ECOG) performance,Incidence of Dose-Limiting toxicity (DLTs),Best Overall Response (BOR) per patient,Overall Response Rate (ORR),Duration of Response (DoR),Clinical Benefit Rate (CBR),Progression Free Survival (PFS),Overall Survival (OS)
Summary
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619
 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06381141
Non-Device Trial